Patent Uncertainty and Drug Launch Timing Pose a Pivotal Question for Corcept

Corcept Therapeutics faces ongoing patent litigation with Teva and antitrust concerns that pose key investment risks. Wolfe Research initiated coverage with Peerperform rating, citing these legal challenges alongside the company's pending FDA decision on relacorilant for hypercortisolism (PDUFA date December 30, 2025). The patent disputes could overshadow revenue prospects if outcomes turn negative, creating uncertainty around the company's ability to diversify beyond its Korlym drug and achieve projected growth targets.